Taban Laura, Stoian Dana, Timar Bogdan, Amzar Daniela, Adela Calin, Motofelea Alexandru, Borlea Andreea, Frisoni Romain, Laguerre Nadege
PhD School Department, "Victor Babes" University of Medicine and Pharmacy Timisoara, 2nd Eftimie Murgu Square, 300041 Timisoara, Romania.
Second Department of Internal Medicine, "Victor Babes" University of Medicine and Pharmacy Timisoara, 2nd Eftimie Murgu Square, 300041 Timisoara, Romania.
J Clin Med. 2022 Sep 18;11(18):5482. doi: 10.3390/jcm11185482.
The presence of steatohepatitis in obese patients can be multifactorial. The current study tries to determine the differences between diabetic and non-diabetic patients regarding the presence of steatohepatitis. We evaluated sequential liver samples and collected the times of bariatric surgery to assess the presence of NASH in patients with obesity, in the circuit of bariatric surgery.
We performed a retrospective study of 49 patients presenting high-grade obesity in the circuit of bariatric surgery, with liver biopsy. The patients underwent bariatric surgery at a single center in France and were followed for 2 years. The liver biopsies were performed intraoperatively on all 49 patients before the bariatric surgery. The primary endpoint of the study was to evaluate the relationships between steatohepatitis/liver fibrosis and the presence of diabetes and to evaluate the current relationships between the biochemical work-ups. Special importance was accorded to the correlations between vitamin D levels and the presence of hepatic steatosis, due to the antifibrogenic pattern in the liver, as shown in many important papers in the field.
Significant correlations were found between the presence of liver fibrosis and the presence of diabetes ( = 0.022), but not regarding the antidiabetic treatment. An important correlation was found between the vitamin D levels and the presence of liver fibrosis, as well as with the levels of A1C hemoglobin and LDL cholesterol levels.
Vitamin D deficiency presents a strong correlation with hepatic steatosis in individuals with morbid obesity. Correcting vitamin D deficiency may present a beneficial role in treating hepatic steatosis, diabetes, and cardiovascular risk in patients with morbid obesity.
肥胖患者发生脂肪性肝炎可能是多因素导致的。本研究旨在确定糖尿病患者与非糖尿病患者在脂肪性肝炎存在情况方面的差异。我们评估了连续的肝脏样本,并收集了减肥手术时间,以评估减肥手术流程中肥胖患者非酒精性脂肪性肝炎(NASH)的存在情况。
我们对49例在减肥手术流程中呈现高度肥胖且接受肝脏活检的患者进行了回顾性研究。这些患者在法国的一个中心接受减肥手术,并随访了2年。所有49例患者均在减肥手术前术中进行肝脏活检。本研究的主要终点是评估脂肪性肝炎/肝纤维化与糖尿病存在之间的关系,以及评估当前生化检查结果之间的关系。由于肝脏中的抗纤维化模式,如该领域许多重要论文所示,维生素D水平与肝脂肪变性存在之间的相关性受到特别重视。
发现肝纤维化的存在与糖尿病的存在之间存在显著相关性(P = 0.022),但与抗糖尿病治疗无关。发现维生素D水平与肝纤维化的存在以及糖化血红蛋白(A1C)水平和低密度脂蛋白胆固醇水平之间存在重要相关性。
维生素D缺乏与病态肥胖个体的肝脂肪变性密切相关。纠正维生素D缺乏可能对治疗病态肥胖患者的肝脂肪变性、糖尿病和心血管风险具有有益作用。